title: Using Molecular Markers to Guide Therapy of Metastatic Colorectal Cancer.
abstract: Colorectal cancer remains one of the most commonly diagnosed cancers with almost one-fourth of patients presenting with metastatic disease at the time of diagnosis. As the repertoire of anticancer agents has expanded to treat colorectal patients with metastatic disease, life expectancies have increased and patients are remaining on therapy for longer periods of time. The exact way in which to combine chemotherapeutic and targeted agents remains a therapeutic challenge in an attempt to preserve efficacy while minimizing toxicity. A crucial need exists for reliable and reproducible biomarkers that can assist in personalizing the most advantageous therapy for patients based on the biology of their tumor that will prevent undue side effects and result in the longest duration of tumor stability. In this review, we discuss the completed studies for each agent currently approved for the treatment of metastatic colon cancer and emphasize a need for further prospective studies to solidify the use of biomarkers in this disease.
authors.affiliation: Department of Medicine, The Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (A.M., B.H.O.).
authors.forename: Autumn
authors.initials: A
authors.lastname: McRee
authors.affiliation: Department of Medicine, The Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (A.M., B.H.O.).
authors.forename: Bert H
authors.initials: BH
authors.lastname: O'Neil
keywords: 5-fluorouracil; EGFR inhibitors; bevacizumab; biomarkers; irinotecan; metastatic colorectal cancer; oxaliplatin